The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Department of Dermatology, Northwestern University Feinberg School of Medicine
-
-
New York
-
New York, New York, United States, 10029
- Department of Dermatology Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has provided informed consent
- Subjects are at least 18 years of age or older at the time of screening
- Female subjects must not be pregnant or breast-feeding
- Female subjects of child-bearing potential with a negative urine pregnancy test and using at least one form of contraception (abstinence allowed)
- Subjects must have a confirmed diagnosis of ARCI (divided phenotypically into ARCI-LI or ARCI-CIE), EI or NS (by genotype or willingness to be genotyped)
- Subjects must be clinically judged to be immunocompetent.
- Subjects will have no allergy to secukinumab or components of the product.
- Subjects will have normal baseline laboratory testing (CMP, CBC, HIV negative, hepatitis B, C negative, QuantiFERON®-TB gold negative)
- Subjects must have an erythema score of at least 18 on IASI and an IASI-E score of 12 (at least moderate severity of erythema) at baseline
Exclusion Criteria:
- Subjects who are unable to give informed consent or assent.
- Subjects without a confirmed diagnosis ARCI, EI, or NS.
- Subjects who have a known allergy to secukinumab.
- Female subjects who are pregnant, considering becoming pregnant, or will breastfeed.
- Subjects who have prior biologic use targeting IL-17A/IL-17 receptor A or IL-12/IL-23 or who have prior use of TNF-alpha blockers.
- Subjects who have used a systemic retinoid within one month prior to initiation.
- Subjects who have used topical retinoids or keratolytics within one week prior to initiation.
- Subjects who have used emollient on the area to be biopsied in the previous 24 hours
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Secukinumab
Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
|
Anti IL-17A antibody
Other Names:
|
|
Placebo Comparator: Placebo
Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction at Week 16 in the Ichthyosis Area Severity Index (IASI)
Time Frame: 16 Weeks
|
Primary Efficacy Endpoint.
The IASI score was modelled after the Eczema Area and Severity Index (EASI) and Psoriasis Area and Severity Index (PASI), commonly used in clinical trials for atopic dermatitis and psoriasis, respectively.
This scale measures erythema and scaling and has a range of 0-48 (sum of a max score of 24 for erythema and 24 for scaling).
A higher score means worse clinical severity.
Mean difference IASI total score at Baseline was compared to IASI total score at Week 16.
|
16 Weeks
|
|
Total Number of Bacterial or Fungal Mucocutaneous Infections Through Week 16
Time Frame: 16 weeks of secukinumab/placebo double blind followed by 32 week open label treatment
|
Primary Safety Endpoint
|
16 weeks of secukinumab/placebo double blind followed by 32 week open label treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Amy Paller, MD, Northwestern University Department of Dermatology
- Principal Investigator: Emma Guttman-Yassky, MD, PhD, Mt. Sinai Hospital Department of Dermatology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Congenital Abnormalities
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Dermatitis
- Skin Diseases, Eczematous
- Skin Abnormalities
- Abnormalities, Multiple
- Keratosis
- Netherton Syndrome
- Ichthyosis
- Dermatitis, Exfoliative
- Ichthyosis, Lamellar
- Ichthyosiform Erythroderma, Congenital
- Hyperkeratosis, Epidermolytic
Other Study ID Numbers
Other Study ID Numbers
- CAIN457AUS05T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.